We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| LogicBio Therapeutics Inc | NASDAQ:LOGC | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.07 | 2.07 | 1.75 | 0 | 01:00:00 |
From Apr 2022 to Apr 2024
By Colin Kellaher
LogicBio Therapeutics Inc. on Monday said it agreed to be acquired by AstraZeneca PLC for about $68 million in a deal supporting the Anglo-Swedish pharmaceutical giant's growth in genomic medicines.
AstraZeneca said it agreed to pay $2.07 a share in cash for LogicBio, more than seven times Friday's closing price of about 27.3 cents for the Lexington, Mass., genetic-medicine company.
AstraZeneca is acquiring LogicBio through Alexion, which it bought last year in a $39 billion deal aimed at expanding its offering of treatments for rare diseases.
Shares of LogicBio, which said it expects the deal to close in four to six weeks, surged to $2.01 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 03, 2022 07:42 ET (11:42 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year LogicBio Therapeutics Chart |
1 Month LogicBio Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
